ERT Virtual Trials COVID-19 Survey Report
With the onset of the COVID-19 pandemic, clinical trial sponsor companies and CROs hastened to implement virtual trial technologies. The virtual visits and digital data exchange would enable them to start or continue studies, despite government mandates requiring patients and staff to stay at home.
During the COVID-19 lockdown, in April and May 2020, ERT surveyed clinical professionals on how the demands of the pandemic were affecting their organizations’ use and planned use of virtual trial technologies. Download the free eBook, Virtual Trials and the COVID-19 Pandemic: The State of Clinical Trials, to learn about their responses and industry trends.
Key takeaways from the report include:
- Organizations will increasingly run full or hybrid virtual clinical trials moving forward because of associated improvements in patient engagement, timeframes, cost effectiveness and data fidelity.
- 82% of clinical trial professionals polled stated that their organizations are incorporating elements of virtual clinical trials due to the pandemic.
- The biggest issue keeping participants up at night is screening for new clinical trials patients (79%)
- The most common ways to collect data in a virtual clinical trial are telehealth (75%) and patient-used devices (75%)
- The primary issues impacting trials over the next six to twelve months are trial management (32%) and patient recruitment and enrollment (25%)
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
